Brainstorm Cell Therapeutics Inc. (BCLI)

Market Cap	11.03M +41.3%
Revenue (ttm)	n/a
Net Income	-10.52M
EPS	-0.95
Shares Out	11.03M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,400
Open	0.940
Previous Close	0.950
Day's Range	0.920 - 1.080
52-Week Range	0.459 - 1.690
Beta	0.26
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About BCLI

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company’s NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the deve...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 19
• Stock Exchange: OTCMKTS
• Ticker Symbol: BCLI

Financial Performance

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 2, 2026

Data Sources Report a data error